Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy

AIDS

Volumn 13, Issue 12, 1999, Pages 1497-1502

  Casado, Jose L ^a   Arrizabalaga, Julio ^b   Montes, Milagros ^b   Martí Belda, Paloma ^a   Tural, Cristina ^c   Pinilla, Javier ^d   Gutierrez, Carolina ^a   Portu, Joseba ^e   Schuurman, Rob ^g   Aguirrebengoa, Koldo ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital Nuestra Senora de Aranzazu   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL SAN PEDRO   (Spain)

^e Hospital Txarrigortu   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cytomegalovirus; HIV; Opportunistic infections; Protease inhibitor; Retinitis

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE;

ARTICLE; CYTOMEGALIC INCLUSION BODY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINITIS; RISK FACTOR; SURVIVAL; VIREMIA; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; DNA, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INCIDENCE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; VIREMIA;

EID: 0032822476     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199908200-00009     Document Type: Article

References (21)

1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS), Clinical findings, diagnosis, and treatment. Ann Intern Med 1988, 108: 585-594.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992, 166: 1223-1227.
3. Chan IS, Neaton JD, Saravolatz LD, Crane LR, Osterberger J. Frequencies of opportunistic diseases prior to death. AIDS 1995, 9: 1145-1151.
4. Pertel P, Hirschtick R, Phari J, Chmiel I, Poggense L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992, 5: 1069-1074.
5. Bowen EF, Wilson P, Cope A, et al. Cytomegalovirus retinitis in AIDS patients. Influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 1996, 10: 1515-1520.
6. Dodt KK, Jacobsen PH, Hofmann B, et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997, 11: F21-F28.
7. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998, 101: 497-502.
8. Brosgarl CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS 1998, 12: 269-277.
9. Casado JL, Perez-Elias MJ, Martí-Belda P, et al. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19: 130-134.
10. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338: 906-908.
11. Mallolas J, Arrizabalaga J, Loncá M, et al. Cytomegalovirus disease in HIV-1 infected patients treated with protease inhibitors [letter]. AIDS 1997, 11: 1785-1787.
12. Schuurman R, Blank B, Pouw W, et al. CMV viral load determination by quantitative DNA PCR in relation to other virological parameters for the diagnosis of CMV infection in HIV-infected individuals. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [Abstract 764].
13. Bowen FF, Sabin CA, Wilson P, et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997, 11: 889-893.
14. Shinkai M, Bozzette SA, Powderly W, Frame P, Spector SA. Utility of urine and leukocyte culture and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for human cytomegalovirus disease. J Infect Dis 1997, 175: 302-308.
15. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996, 334: 1491-1497.
16. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4 T-cell phenotype and depletion within the CD4 T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3: 533-540.
17. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173. 321-329.
18. Brosgart CL, Pulling C, Chaloner K, et al. Prevalence of asymptomatic CMV retinitis in AIDS patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [Abstract 756].
19. Michaels S, Clark R, Kissinger P: Differences in the incidence rates of opportunistic processes before and after the availability of protease inhibitors. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, July 1998 [Abstract 180].
20. Boivin G, Handfield J, Toma E, Lalonde R, Murray G, Bergeron MG: Evaluation of the Amplicor CMV test for the diagnosis of CMV disease in HIV patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 27 September-1 October 1997 [Abstract H104].
21. Gerna G, Baldanti F, D'Arminio Monforte A, et al. Sustained disappearance of human CMV in blood of AIDS patients following HAART. 12th World AIDS Conference, Geneva, July 1998 [Abstract 22237].